10.59 0.00 (0.00%)
After hours: 4:46PM EST
| Previous Close | 11.39 |
| Open | 11.43 |
| Bid | 10.20 x 900 |
| Ask | 13.39 x 1800 |
| Day's Range | 10.48 - 11.50 |
| 52 Week Range | 10.48 - 20.55 |
| Volume | 295,928 |
| Avg. Volume | 181,568 |
| Market Cap | 307.529M |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NEW YORK, Nov. 16, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology.
NEW YORK, Nov. 08, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology.
NEW YORK, Nov. 02, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology.
NEW YORK, Oct. 16, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. (“Stemline” or the “Company”) (STML) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Stemline, headquartered in New York, NY, is a clinical-stage biopharmaceutical company focused on the development and commercialization of oncology therapies. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.
NEW YORK, Sept. 28, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, is ...
NEW YORK, Sept. 05, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will ...
Propanc BioPharma, Inc ( PPCB ) Market Cap: 2.4 M, current share price: $0.07 HENDERSON, NV / ACCESSWIRE / June 19, 2018 / Propanc Biopharma Inc. , a clinical stage biopharmaceutical company focusing on ...
LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Stemline Therapeutics, Inc. (NASDAQ: STML), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=STML as the Company's latest news hit the wire. On May 18, 2018, the Company announced that its SL-401 will be the subject of three clinical presentations, including an oral presentation on the pivotal blastic plasmacytoid dendritic cell neoplasm (BPDCN) program, at the upcoming 23rd Congress of the European Hematology Association (EHA), to be held from June 14-17, 2018, in Stockholm, Sweden. Updated data from the ongoing Phase-2 trial in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) will also be presented.
Levi & Korsinsky announces it has commenced an investigation of Stemline Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
NEW YORK , May 1, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...